SEC Filings
Biodesix Shares Plunge About 47% As Company Resets Revenue Forecast To $101–$103 Million
Testing volumes rose 24%, but sales-team shortfalls, seasonal ordering and delayed development projects held growth below management’s expectations.
BDSX
Biodesix (BDSX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Biodesix Parts Ways With Chief Commercial Officer Kieran O’Kane, Who Qualifies For Separation Benefits
The departure comes at a diagnostics business whose lung-testing operation generated $79.2 million in revenue in 2025.
Earnings
Biodesix CEO Disputes 'Record October' Framing As Guidance Implies 2% Fourth-Quarter Lung Test Growth
The CFO said the midpoint implies 2% year-over-year growth once last year's back-claim collections are removed, against full-year revenue guidance of $101 million to $103 million.